Immunome (NASDAQ:IMNM) Upgraded to "Strong-Buy" at The Goldman Sachs Group

Immunome (NASDAQ:IMNM - Get Free Report) was upgraded by equities researchers at The Goldman Sachs Group to a "strong-buy" rating in a research report issued to clients and investors on Monday,Zacks.com reports.

• 3 Small-Cap Stocks With Big Growth Potential

Several other research firms have also recently weighed in on IMNM. Guggenheim restated a "buy" rating and issued a $25.00 price objective on shares of Immunome in a research report on Monday, August 25th. JPMorgan Chase & Co. lowered their price objective on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Wedbush restated an "outperform" rating and issued a $21.00 price objective on shares of Immunome in a research report on Thursday, September 18th. Evercore ISI began coverage on shares of Immunome in a research report on Friday, August 22nd. They issued an "outperform" rating and a $18.00 price objective for the company. Finally, Craig Hallum began coverage on shares of Immunome in a research note on Friday, September 5th. They issued a "buy" rating and a $26.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $23.20.

Get Our Latest Stock Report on Immunome

Immunome Trading Up 4.0%

IMNM opened at $9.77 on Monday. The stock has a market capitalization of $850.38 million, a PE ratio of -3.17 and a beta of 1.92. Immunome has a 1-year low of $5.15 and a 1-year high of $15.40. The firm has a 50-day moving average price of $10.03 and a two-hundred day moving average price of $8.84.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.02. The firm had revenue of $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. On average, research analysts predict that Immunome will post -2.21 EPS for the current year.

Institutional Trading of Immunome

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. raised its holdings in shares of Immunome by 37.4% in the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company's stock valued at $50,843,000 after purchasing an additional 2,054,640 shares during the last quarter. Redmile Group LLC raised its holdings in shares of Immunome by 11.0% in the first quarter. Redmile Group LLC now owns 5,361,187 shares of the company's stock valued at $36,081,000 after purchasing an additional 533,161 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Immunome by 43.4% in the first quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company's stock valued at $28,987,000 after purchasing an additional 1,303,753 shares during the last quarter. EcoR1 Capital LLC increased its holdings in Immunome by 5.2% during the first quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company's stock worth $27,454,000 after buying an additional 200,000 shares during the last quarter. Finally, Primecap Management Co. CA increased its holdings in Immunome by 1,115.7% during the first quarter. Primecap Management Co. CA now owns 3,413,700 shares of the company's stock worth $22,974,000 after buying an additional 3,132,900 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Further Reading

• Five stocks we like better than Immunome
• What is an Earnings Surprise?
• How The Weak Dollar Is Fueling These Global Stock Surges
• What Investors Need to Know About Upcoming IPOs
• 3 Recession-Ready Stocks That Thrive When the Economy Sputters
• How to invest in marijuana stocks in 7 steps
• 3 Automation-Focused Stocks Flying Under the Radar

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immunome Right Now?

Before you consider Immunome, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.

While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here